VistaGen TherapeuticsNASDAQ: VTGN

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year ended March 31, 2024, and provided a corporate update. “Vistagen's fiscal 2024 proved to be a year full of remarkable accomplishments. Most notably, with.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced it will host a conference call and webcast on Tuesday, June 11, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2024 ended March 31, 2024 and provide a corporate update. Event: Vistagen Fis.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters highlighting fasedienol, its investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and itruvone, its investigational pherine candidate in Phase 2.

Vistagen (Nasdaq: VTGN), a biopharmaceutical company focused on neuroscience, will be presenting posters on clinical trial data for fasedienol and PH80 at an upcoming event.

Vistagen Therapeutics has proprietary platform technologies for developing innovative drugs for mental health disorders. The company's pipeline includes candidates for social anxiety disorder, major depressive disorder, vasomotor symptoms, and more. Vistagen's financial position is strong, with ample liquidity to support operations and fund clinical development programs.

VistaGen Therapeutics is developing CNS drugs for anxiety, depression, and other disorders, with Fasedienol in phase 3 clinical trials. Fasedienol has advantages as a non-systemic, low-abuse anxiolytic and is seeking Breakthrough Therapy Designation. VTGN's diverse product pipeline includes treatments for social anxiety disorders, major depressive disorder, menopause symptoms, and more.

The mean of analysts' price targets for VistaGen Therapeutics, Inc. (VTGN) points to a 160% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Vistagen (VTGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Positive results achieved in phase 3 PALISADE-2 study for Fasedienol, a potential new treatment for social anxiety disorder. It is estimated that there are roughly 25 million people in the United States with this disorder. Itruvone is being advanced for the treatment of patients with major depressive disorder; A phase 2b study is expected to start in the 2nd half of 2024.